Competitive bioreactor hens on the horizon.
The hen has long held promise as a low-cost, high-yield bioreactor for the production of human biopharmaceuticals in egg whites using genetic engineering. Two separate reports have recently appeared indicating the production of substantial levels of human monoclonal and single chain antibodies (>3 mg and >150 mg, respectively) in eggs of transgenic hens. These promising findings indicate that the hen is close to becoming a competitive manufacturing platform for the production of human biopharmaceuticals.
Ivarie
Robert
R
Department of Genetics, University of Georgia, Athens, GA 30602-7223, USA. ivarie@uga.edu
D000818:Animals; D030801:Animals, Genetically Modified / Q000235:genetics* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000235:genetics; D019149:Bioreactors; D002645:Chickens / Q000235:genetics* / Q000378:metabolism; D004527:Egg Proteins / Q000096:biosynthesis* / Q000235:genetics; D005818:Genetic Engineering / Q000379:methods / Q000639:trends; D006801:Humans; D009928:Organ Specificity / Q000235:genetics; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000235:genetics
D000911:Antibodies, Monoclonal; D004527:Egg Proteins; D011994:Recombinant Proteins